Table 2.
Patient characteristics of best supportive care and curative‐intent groups
| Characteristic | Curative (n = 50) | Best supportive care (n = 33) | |
|---|---|---|---|
| Outcome—no. (%) | |||
| Deceased | 37 (74) | 33 (100) | |
| Survived | 13 (26) | 0 (0) | |
| Sex—no. (%) | |||
| Male | 29 (58) | 17 (48.5) | P = .561 |
| Female | 21 (42) | 16 (51.5) | |
| Age at time of allogeneic HSCT—y | |||
| Median (interquartile range) | 53 (39‐58) | 58 (50‐64) | P = .043 |
| Range | 18‐71 | 26‐68 | |
| Prognostic class at time of AML diagnosis—no. (%) | |||
| Good risk | 2 (4) | 1 (3) | Pearson's r = .226; P = .040 |
| Intermediate risk | 15 (30) | 4 (12) | |
| Poor risk | 21 (42) | 14 (42) | |
| Very poor risk | 12 (24) | 14 (42) | |
| WHO classification—no. (%) | |||
| AML with recurrent genetic abnormalities | 19 (38) | 14 (42) | |
| AML with myelodysplasia‐related changes | 5 (10) | 4 (12) | |
| Therapy‐related myeloid neoplasms | 3 (6) | 3 (9) | |
| AML NOS | 21 (42) | 11 (33) | |
| Other | 2 (4) | 1 (3) | |
| Transplantation type—no. (%) | |||
| MUD (10/10) | 31 (62) | 22 (67) | |
| SIB | 8 (36) | 10 (30) | |
| CB | 1 (2) | 1 (3) | |
| Conditioning regimen—no. (%) | |||
| Myeloablative | 7 (14) | 1 (3) | P = .137 |
| Reduced intensity or FLAMSA | 43 (86) | 32 (97) | |
| Bone marrow blast count at time of relapse—% (n = 74) | |||
| Median (interquartile range) | 21 (10‐50) | 38 (20‐67) | P = .025† |
| Range | 0‐74 | 10‐99 | |
| No data | 4 | 5 | |
| Time between allogeneic HSCT and relapse—wk | |||
| Median (interquartile range) | 21 (14‐47) | 21 (6‐28) | P = .047 |
| Range | 5‐187 | 3‐63 | |
| Early vs late relapse—no. (%) | |||
| Early (<3 mo) | 11 (22) | 12 (36) | P = .119 |
| Late (≥3 mo) | 39 (78) | 21 (64) | |
| Time between relapse and death—wk | |||
| Median (interquartile range) | 16 (6‐31) | 3 (1‐10) | P < .001 |
| Range | 2‐119 | 0‐37 | |
†
When n = 4 patients with isolated CNS relapse are excluded, the difference in bone marrow blast counts between the two groups is not significant.